Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

The drug is approved both to treat and prevent migraine in adults and is one of ... GlobalData said recently it expects Nurtec ODT to reach a peak of around $2 billion in annual sales in 2029 ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner generated revenue for Pfizer of nearly $7.4 billion last year. It loses patent ...

Atogepant was approved last September as Qulipta for migraine prevention in the US – where Vydura is known as Nurtec ODT and was cleared for acute migraine treatment in early 2020 and for ...

Both Qulipta and Nurtec ODT belong to a group of drugs called CGRP antagonists. Both drugs help prevent migraine episodes. Nurtec ODT also treats migraine episodes. One review of studies suggests ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...